Pa­tient dies in a trou­bled HBV drug pro­gram — forc­ing de­vel­op­ers to scrap the drug and shift fo­cus. To STING

Things have just gone from bad to worse at Hop­kin­ton, MA-based Spring Bank Phar­ma­ceu­ti­cals.

Re­searchers say that a pa­tient died in their Phase IIb study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.